Osimertinib Plus Bevacizumab Does Not Improve PFS in EGFR-Mutated NSCLC
September 18th 2021Osimertinib (Tagrisso) plus bevacizumab does not produce a superior progression-free survival (PFS) benefit over osimertinib monotherapy in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation. However, for patients who have a history of smoking or an exon 20 deletion, the combination may prove beneficial.
Read More
CheckMate 9ER Regimen Shows Efficacy Regardless of Prior Nephrectomy in RCC
September 18th 2021An exploratory subgroup analysis of the CheckMate 9ER trial discussed at the 2021 ESMO Congress showed significant benefits to progression-free survival for patients with renal cell carcinoma on nivolumab and cabozantinib regardless if they had prior nephrectomy.
Read More
pCR, EFS, Improved with Neoadjuvant Carboplatin Plus Paclitaxel, Without Veliparib in TNBC
September 17th 2021Pathological complete response rates and event-free survival in patients with treatment-naïve triple-negative breast cancer were improved with The addition of carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide.
Read More
Compared indirectly with real-world data of patients treated with standard of care, mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy.
Read More
Mobocertinib Global Maximum-Tolerated Dose is Found Tolerable in Japanese Patients With NSCLC
September 16th 2021Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts, leading to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in Japanese patients with non–small cell lung cancer.
Read More
High Responses to Dostarlimab in Endometrial Cancer Linked to TMB-H Status
September 16th 2021High responses to single-agent dostarlimab-gxly were seen in patients with endometrial cancer who had a high tumor mutational burden, irrespective of mismatch repair or microsatellite stability status.
Read More
Comparable Safety Profile Seen With The Addition of Darolutamide to ADT Among Patients With nmCRPC
September 16th 2021Compared with a placebo, darolutamide demonstrated a similar safety profile in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) continuing androgen-deprivation therapy, with comparable adverse event onset and occurrence rates.
Read More
Darolutamide Improves Episodic Memory Enzalutamide in Men With mCRPC Compared to Enzalutamide
September 16th 2021Darolutamide was statistically significantly associated with better episodic memory over enzaluamide, according to computerized cognitive assessment in men with metastatic castration-resistant prostate cancer.
Read More
Limited Activity Shown With Durvalumab/Tremelimumab in Advanced NETs Subtypes
September 22nd 2020Results from the DUNE trial of durvalumab added to tremelimumab in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins showed limited activity, according to a presentation held during the 2020 European Society of Medical Oncology Virtual Congress.
Read More
Trabectedin Plus Durvalumab Feasible for Treatment of Soft Tissue Sarcoma
September 21st 2020Preliminary activity was observed in an unselected group of patients with miscellaneous soft tissue sarcoma treated with trabectedin in combination with durvalumab in the phase 1b TRAMUNE trial. The results presented during the 2020 European Society of Medical Oncology Virtual Congress demonstrate the feasibility of utilizing this combination in soft tissue sarcoma.
Read More
Evaluating Next Steps for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
September 21st 2020Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.
Read More
Cabozantinib Doublet Achieves Early Clinical Activity in Advanced ccRCC
September 21st 2020Patients with advanced clear cell renal cell carcinoma treated with cabozantinib in combination with atezolizumab in the phase 1b COSMIC-021 study, had promising clinical activity, according to results from the study presented during the 2020 European Society of Medical Oncology Virtual Congress.
Read More
Pembrolizumab Extends Progression-Free Survival in Rare Sarcoma Subtypes
September 21st 2020Prolonged progression-free survival was observed with pembrolizumab monotherapy in patients with selected rare sarcoma subtypes treated in the phase 2 AcSé basket study, according to a presentation during the 2020 European Society of Medical Oncology Virtual Congress.
Read More
Atezolizumab Plus Bevacizumab and Chemotherapy Misses PFS End Point in Ovarian Cancer Trial
September 21st 2020In patients with newly diagnosed stage III/IV ovarian cancer, adding atezolizumab to a backbone combination of bevacizumab and chemotherapy did not improve progression-free survival, missing the primary end point of the phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial presented during the virtual 2020 European Society of Medical Oncology Congress.
Read More
Osimertinib Achieves Extended Disease-Free Survival in EGFR-Mutant NSCLC
September 21st 2020In patients with early-stage EGFR mutated non–small cell lung cancer following complete tumor resection, treatment with osimertinib reduced the risk for central nervous system death or progression by 82%, findings presented during the EMSO Virtual Congress 2020.
Read More
Palbociclib/Fulvestrant Prolongs PFS in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer
September 21st 2020Patients with endocrine-sensitive hormone receptor–positive, HER2-negative metastatic breast cancer, treated with Frontline fulvestrant in combination with palbociclib experienced improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone, achieving the primary end point of the phase 2 FLIPPER trial.
Read More
Larotrectinib Induces Promising Response Rate in Patients With Differentiated Thyroid Cancer
September 21st 2020Larotrectinib as treatment of patients with TRK fusion-positive thyroid cancer had rapid and durable disease control, with the highest response rates observed in the differentiated thyroid cancer population.
Read More
Molecularly-Guided Therapy Improves Responses in mRCC
September 21st 2020The use of molecularly-directed frontline therapy enriched responses in patients with metastatic clear cell renal cell carcinoma, demonstrating clinical evidence to support further use, according to findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial.
Read More
Pembrolizumab Plus Chemotherapy Enters Frontline Treatment Landscape of Advanced Esophageal Cancer
September 21st 2020In the phase 3 KEYNOTE-590 clinical trial, frontline pembrolizumab plus chemotherapy demonstrated a significant improvement in overall survival, progression-free survival, and objective response rates versus chemotherapy only in patients with locally advanced unresectable or metastatic esophageal cancer, result presented during the 2020 ESMO Virtual Congress show.
Read More
Survival Improvement Observed with Cemiplimab in Frontline Advanced PD-L1+ NSCLC
September 21st 2020In the phase 3 EMPOWER-Lung 1 trial, patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cells, had a significant improvement in overall survival and progression-free survival with cemiplimab-rwlc monotherapy compared with platinum-doublet chemotherapy.
Read More
Nivolumab Plus Chemotherapy Extends PFS With Durable Responses in Gastric/GEJ Cancers
September 21st 2020In the phase 3 ATTRACTION-4 study, nivolumab added to chemotherapy led to a statistically significant improvement in progression-free survival and induced higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer, according to results presented during the 2020 ESMO Virtual Congress.
Read More
Non-Superiority of Weekly Dose-Dense Chemotherapy Versus SOC Shown in Epithelial Ovarian Cancer
September 21st 2020Patients with epithelial ovarian cancer treated with weekly dose-dense chemotherapy in the ICON8 clinical trial experienced similar progression-free survival and overall survival as patients treated with the standard-of-care.
Read More